c-Kit and c-kit mutations in mastocytosis and other hematological diseases

Journal of Leukocyte Biology

Volumn 67, Issue 2, 2000, Pages 135-148

  Boissan, M ^a   Feger, F ^a   Guillosson, J J ^a   Arock, M ^a  

^a Faculty of Pharmacy   (France)

Author keywords

Mast cell; Mastocystosis; Mutation; Stem cell factor

Indexed keywords

AMINO ACID; CHEMOKINE; CYTOKINE; INTERLEUKIN 3; MYOSIN LIGHT CHAIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; STEEL FACTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TYROSINE;

CELL DIFFERENTIATION; CELL PROLIFERATION; GENE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; INTERNALIZATION; LEUKEMIA; MAST CELL; MASTOCYTOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033800085     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.67.2.135     Document Type: Review

References (129)

1. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
2. Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4
3. Structure-function relationships of stem cell factor: An analysis based on a series of human-murine stem cell factor chimera and the mapping of a neutralizing monoclonal antibody
4. Stem cell factor
5. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
6. The kit ligand: A cell surface molecule altered in steel mutant fibroblasts
7. Stem cell factor (SCF), a novel hematopoietic growth factor and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter
8. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms
9. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor
10. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction
11. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
12. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor
13. Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1
14. Coexpression of the c-kit and stem cell factor genes in breast carcinomas
15. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors
16. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group
17. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase
18. Mast cells
19. Systemic mast cell disease. Analysis of 58 cases and literature review
20. Classification and diagnosis of mastocytosis: Current status
21. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells
22. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture
23. + pluripotent progenitor cells
24. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand
25. Is mastocytosis a mast cell neoplasia or a reactive hyperplasia? Clues from the study of mast cell growth factor
26. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
27. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
28. Activation of the feline c-fms proto-oncogene: Multiple alterations are required to generate a fully transformed phenotype
29. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential
30. Genetics. One gene - Four syndromes
31. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis
32. Human skin/SCID mouse chimeras as an in vivo model for human cutaneous mast cell hyperplasia
33. Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo
34. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation
35. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain
36. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3
37. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
38. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells
39. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
40. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior
41. c-Kit mutation in a population of patients with mastocytosis
42. A new c-kit mutation in a case of aggressive mast cell disease
43. C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors
44. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
45. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
46. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
47. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms
48. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region
49. Blood findings in generalized mastocytosis: Evidence of frequent simultaneous occurrence of myeloproliferative disorders
50. Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis
51. Congenital bullous mastocytosis with myeloproliferative disorder and c-kit mutation
52. Acute nonlymphocytic leukemia in systemic mastocytosis with biclonal gammopathy
53. Systemic mastocytosis associated with acute myeloid leukaemia: Report of two cases and detection of the c-kit mutation Asp-816 to Val
54. c-Kit activating mutations and mast cell proliferation in human leukemia
55. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product
56. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors
57. Relationship between c-Kit expression and proliferation in acute myeloblastic leukemia cell lines
58. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis
59. C-kit receptor (CD117) expression in acute leukemia
60. Biological characteristics of CD7(+) acute leukemia
61. CD117/CD34 expression in leukemic blasts
62. C-kit receptors in childhood malignant lymphoblastic cells
63. Synergistic action of interleukin-2 and Steel factor (SLF) on a human T lymphoblastoid cell line
64. Expression and regulation of c-kit receptor and response to stem cell factor in childhood malignant T-lymphoblastic cells
65. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase
66. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity
67. c-Kit point mutation of extracellular domain in patients with myeloproliferative disorders
68. c-Kit point mutation in patients with myeloproliferative disorders
69. C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukemia
70. The cellular basis for enhancement interactions between stem cell factor and the colony stimulating factors
71. Role of the KIT protooncogene in normal and malignant human hematopoiesis
72. Stage-specific expression of c-kit protein by murine hematopoietic progenitors
73. Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C
74. Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase
75. The Steel/W transduction pathway: Kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor
76. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells
77. The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells
78. Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway
79. Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation
80. c-Kit ligand stimulates tyrosine phosphorylation of the c-Cb protein in human hematopoietic cells
81. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidyl-inositol 3-kinase, and p120 (CBL)
82. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136
83. Tec kinase associates with c-kit and is tyrosine phosphorylated and activated following stem cell factor binding
84. The MATK tyrosine kinase interacts in a specific and SH2-dependent manner with c-Kit
85. Steel factor stimulates the tyrosine phosphorylation of the proto-oncogene product, p95vav, in human hemopoietic cells
86. p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells
87. Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase
88. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor
89. JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor
90. Stat1 associates with c-kit and is activated in response to stem cell factor
91. Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro
92. Lck associates with and is activated by Kit in a small cell lung cancer cell line: Inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1
93. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
94. Steel factor enhances integrin-mediated tyrosine phosphorylation of focal adhesion kinase (pp125FAK) and paxillin
95. Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand
96. Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1
97. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1
98. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain
99. Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C
100. Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells
101. Involvement of phosphatidylinositol 3'-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release
102. Kit signaling through PI 3-kinase and Src kinase pathways: An essential role for Rac1 and JNK activation in mast cell proliferation
103. Essential roles of Lyn in fibronectin-mediated filamentous actin assembly and cell motility in mast cells
104. SCF/c-kit receptor-mediated arachidonic acid liberation in rat mast cells. Involvement of PLD activation associated tyrosine phosphorylation
105. Stem cell factor-induced signal transduction in rat mast cells. Activation of phospholipase D but not phosphoinositide-specific phospholipase C in c-kit receptor stimulation
106. Pharmacological study of stem-cell-factor-induced mast cell histamine release with kinase inhibitors
107. Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3'-kinase, and protein kinase C
108. Ligand-dependent polyubiquitination of c-kit gene product: A possible mechanism of receptor down modulation in M07e cells
109. 2+ influx dependence for ligand-stimulated internalization of the c-Kit receptor
110. Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation
111. Structure-function analyses of the kit receptor for the steel factor
112. Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells
113. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines
114. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site
115. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1
116. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav
117. A single point mutation switches the specificity of group III Src homology (SH) 2 domains to that of group I SH2 domains
118. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
119. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains
120. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
121. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase
122. CML and apoptosis: The ceramide pathway
123. Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells
124. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
125. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
126. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
127. Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes
128. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells
129. c-Kit receptor signaling through its phosphatidylinositide-3'-kinase-binding site and protein kinase C: Role in mast cell enhancement of degranulation, adhesion, and membrane ruffling